Literature DB >> 30737677

Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto's thyroiditis.

Azusa Harada1, Emiko Nomura1, Kumiko Nishimura1, Mitsuru Ito2, Hiroshi Yoshida2, Akira Miyauchi2, Mitsushige Nishikawa2, Ichiro Shiojima1, Nagaoki Toyoda3.   

Abstract

PURPOSE: The serum free triiodothyronine (FT3)/free thyroxine (FT4) ratio in patients with huge goitrous Hashimoto's thyroiditis (HG-HT) is relatively high. We investigated the cause of high FT3/FT4 ratios.
METHODS: We measured the serum FT3, FT4, and thyrotropin (TSH) levels of seven patients with HG-HT who had undergone a total thyroidectomy. Eleven patients with papillary thyroid carcinoma served as controls. The activities and mRNA levels of type 1 and type 2 iodothyronine deiodinases (D1 and D2, respectively) were measured in the thyroid tissues of HG-HT and perinodular thyroid tissues of papillary thyroid carcinoma.
RESULTS: The TSH levels in the HG-HT group were not significantly different from those of the controls. The FT4 levels in the HG-HT group were significantly lower than those of the controls, whereas the FT3 levels and FT3/FT4 ratios were significantly higher in the HG-HT group. The FT3/FT4 ratios in the HG-HT group who had undergone total thyroidectomy and received levothyroxine therapy decreased significantly to normal values. Both the D1 and D2 activities in the thyroid tissues of the HG-HT patients were significantly higher than those of the controls. However, the mRNA levels of both D1 and D2 in the HG-HT patients' thyroid tissues were comparable to those of the controls. Interestingly, there were significant correlations between the HG-HT patients' D1 and D2 activities, and their thyroid gland volume or their FT3/FT4 ratios.
CONCLUSIONS: Our results indicate that increased thyroidal D1 and D2 activities may be responsible for the higher serum FT3/FT4 ratio in patients with HG-HT.

Entities:  

Keywords:  Hashimoto’s thyroiditis; Iodothyronine deiodinase; Thyroid gland; Thyroid hormone metabolism

Mesh:

Substances:

Year:  2019        PMID: 30737677     DOI: 10.1007/s12020-019-01855-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  18 in total

1.  Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation.

Authors:  B Gereben; C Goncalves; J W Harney; P R Larsen; A C Bianco
Journal:  Mol Endocrinol       Date:  2000-11

2.  Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.

Authors:  Y Murakami; J Takamatsu; S Sakane; K Kuma; N Ohsawa
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

3.  Type 2 iodothyronine deiodinase expression is upregulated by the protein kinase A-dependent pathway and is downregulated by the protein kinase C-dependent pathway in cultured human thyroid cells.

Authors:  Y Imai; N Toyoda; A Maeda; T Kadobayashi; G Fangzheng; M Nishikawa; T Iwasaka
Journal:  Thyroid       Date:  2001-10       Impact factor: 6.568

Review 4.  The deiodinase family of selenoproteins.

Authors:  D L St Germain; V A Galton
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

5.  Type 2 iodothyronine deiodinase is highly expressed in human thyroid.

Authors:  D Salvatore; H Tu; J W Harney; P R Larsen
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

6.  Thyroglobulin gene mutations producing defective intracellular transport of thyroglobulin are associated with increased thyroidal type 2 iodothyronine deiodinase activity.

Authors:  Yasuhiko Kanou; Akira Hishinuma; Katsuhiko Tsunekawa; Koji Seki; Yutaka Mizuno; Haruki Fujisawa; Tsuneo Imai; Yoshitaka Miura; Tetsuro Nagasaka; Chizumi Yamada; Tamio Ieiri; Masami Murakami; Yoshiharu Murata
Journal:  J Clin Endocrinol Metab       Date:  2007-01-23       Impact factor: 5.958

7.  TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.

Authors:  Mitsuru Ito; Akira Miyauchi; Shinji Morita; Takumi Kudo; Eijun Nishihara; Minoru Kihara; Yuuki Takamura; Yasuhiro Ito; Kaoru Kobayashi; Akihiro Miya; Sumihisa Kubota; Nobuyuki Amino
Journal:  Eur J Endocrinol       Date:  2012-06-18       Impact factor: 6.664

8.  Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.

Authors:  Peter Laurberg; Henrik Vestergaard; Soren Nielsen; Stig E Christensen; Torben Seefeldt; Kjeld Helleberg; Klaus M Pedersen
Journal:  J Clin Endocrinol Metab       Date:  2007-03-27       Impact factor: 5.958

9.  Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease.

Authors:  Mitsuru Ito; Nagaoki Toyoda; Emiko Nomura; Yuuki Takamura; Nobuyuki Amino; Toshiji Iwasaka; Junta Takamatsu; Akira Miyauchi; Mitsushige Nishikawa
Journal:  Eur J Endocrinol       Date:  2010-10-11       Impact factor: 6.664

10.  Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels.

Authors:  B W Kim; G H Daniels; B J Harrison; A Price; J W Harney; P R Larsen; A P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

View more
  1 in total

1.  Giant cervical goiter in Hashimoto's thyroiditis: A case report.

Authors:  Tang Tao; Yang Gang; Sun Ji; Chen Xiao-Li; Li Wei-Nan; Li Qiang; Zhu Jian-Jiao; Xiong Yong-Fu; Li Jing-Dong
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.